NEW YORK (GenomeWeb News) – Scientists in the Czech Republic and Slovakia will use a breast cancer test from OncoVista Innovative Therapies subsidiary AdnaGen in a cancer research effort focused on using the predictive assay in clinics, the San Antonio-based firm said today.

Under the agreement, Tataa Molecular Diagnostics will partner with the Institute of Biotechnology of the Czech Academy of Science on the COHERTA study, which is funded in part through a grant from Hoffman-La Roche's Czech and Slovak subsidiaries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.